

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



spectrum
CHEMICAL MFG CORP
800.772.8786
SpectrumChemical.com

Spectrum Offers 1200+ USP/NF cGMP Products.
Order Your 2016 USP Catalog!

[Click Here](#)



1. [Pfizer and Allergan Terminate \\$160 Billion Merger; New US Treasury Department Action at Play](#)

Pfizer and Allergan have called off their proposed \$160 billion merger citing the US Department of Treasury's issuance of temporary and proposed regulations to further reduce the benefits of and limit the number of corporate inversions, a move that the companies said created an adverse tax law change. This is the second recent time that Treasury action has led to the termination of a pharmaceutical mega merger, the other being AbbVie's decision to end his \$55 billion acquisition of Shire in 2014. [Read More](#)

2. [Allergan, Heptares Sign \\$3.3 Billion Small-Molecule Pact](#)

Allergan's wholly owned subsidiary, Allergan Pharmaceuticals International Limited, and Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation, a biopharmaceutical company, have agreed to a pact under which Allergan will license exclusive global rights to a broad portfolio of subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer's disease, in a deal valued up to \$3.3 billion. [Read More](#)

3. [Gilead Sciences To Acquire Nimbus Therapeutics in Potential \\$1.2 Billion Deal](#)

Gilead Sciences and Nimbus Therapeutics, LLC, a Cambridge, Massachusetts, biotechnology company, have signed a definitive agreement under which Gilead will acquire Nimbus Apollo, Inc., a wholly owned subsidiary of Nimbus Therapeutics, and its acetyl-CoA carboxylase inhibitor program. Nimbus Therapeutics will receive an upfront payment of \$400 million with the potential to receive an additional \$800 million in development-related milestones. [Read More](#)

4. [Lilly to Invest \\$40 Million in Small-Molecule Continuous Manufacturing Facility](#)

Eli Lilly and Company will invest EUR 35 million (\$40 million) in a new manufacturing facility using continuous manufacturing technology at its campus in Kinsale, Ireland. The facility will be used to carry out the development and commercialization of a number of Lilly's small-molecule pipeline products that are currently undergoing late-stage clinical trials. This development will see the Kinsale site becoming the center of excellence for continuous manufacturing for active pharmaceutical ingredients for Lilly worldwide. [Read More](#)

5. [Eisai Signs Russian Manufacturing Pact](#)

The Japanese pharmaceutical company, Eisai, and PharmStandard, a Russian pharmaceutical company, have signed cooperation agreements for the localized production of Eisai products in Russia. These agreements relate to Eisai's global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company's global epilepsy therapy, Fycompa (perampanel). [Read More](#)

6. [FDA OKs and EMA Advisory Committee Recommends Remicade Biosimilar](#)

The FDA has approved Inflectra (infliximab-dyyb) for multiple indications, a biosimilar to Janssen Biotech, Inc.'s Remicade (infliximab). Inflectra is manufactured by Celltrion, based in Yeonsu-gu, Incheon, Republic of Korea, for Hospira (now part of Pfizer following Pfizer's \$17 billion acquisition of Hospira in 2015). Also, the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for the marketing authorization of Flixabi, an infliximab biosimilar candidate by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen. Remicade was one of Johnson & Johnson's top-selling pharmaceuticals in 2015 with global sales of \$6.56 billion. [Read More](#)

7. [Teva, Takeda Establish New Generics JV in Japan](#)

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited have established Teva Takeda Yakuhin Ltd., a joint venture focusing on generic drugs in Japan. The companies had first announced their intent to establish the joint venture in 2015. [Read More](#)

8. [Juno Therapeutics, WuXi AppTec Form New Cell Therapy Company in China](#)

Juno Therapeutics, a biopharmaceutical company focused on developing cancer immunotherapies, and WuXi AppTec, an R&D capability and technology platform company, have started a new company in China, JW Biotechnology (Shanghai) Co., Ltd., focused on cell therapies. The new company seeks to leverage Juno's chimeric antigen receptor and T cell receptor technologies together with WuXi AppTec's R&D and manufacturing platform and local expertise to develop cell-based immunotherapies for patients with hematologic and solid organ cancers. [Read More](#)

9. [Pfizer, IBM Sign Digital Health Pact for Parkinson's Disease](#)

Pfizer and IBM have formed a research collaboration to develop remote monitoring solutions for use by clinicians to deliver care to patients with Parkinson's disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The two companies project that the system will move into initial clinical testing quickly. [Read More](#)

10. [Regeneron, AstraZeneca's MedImmune Form ADC Pact](#)

Regeneron Pharmaceuticals and MedImmune, the global biologics research and development arm of AstraZeneca, have entered into a licensing agreement under which Regeneron will use MedImmune's pyrrolobenzodiazepine-based warhead and linker technology to produce antibody drug conjugates (ADCs) as potential cancer treatments. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org